Group ID|Group Name|Treatment Sequence|Treatment Age|Treatment Type|Treatment Quantity|Treatment Unit|Treatment Application|Treatment Remarks|No of individuals in study|Species|Strain|Sex|Age|Group Endpoints|Individual ID|Group ID|Age at death|Pathology type|Pathology location|Pathology Description|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-1|1|233|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 549 - carcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-2|1|375|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-3|1|419|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-4|1|422|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-5|1|498|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-6|1|504|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-7|1|515|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-8|1|522|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-9|1|526|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-10|1|529|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-11|1|533|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-12|1|538|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|horned,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-13|1|555|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-14|1|559|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-15|1|575|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-16|1|582|Neoplasia unclassified|Central nervous system among nervous system|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-17|1|587|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-18|1|590|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-19|1|594|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-20|1|608|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-21|1|614|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-22|1|618|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-23|1|630|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-24|1|630|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-25|1|632|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-26|1|633|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-27|1|635|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-28|1|635|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-29|1|638|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-30|1|638|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-31|1|643|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-32|1|649|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-33|1|655|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-34|1|664|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-35|1|674|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-36|1|674|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-37|1|680|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-38|1|681|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-39|1|681|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-40|1|683|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-41|1|683|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-42|1|685|Neoplasia systemic|Haematolymphatic system|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-43|1|687|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-44|1|688|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-45|1|690|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-46|1|692|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-47|1|692|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-48|1|694|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-49|1|695|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-50|1|711|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-51|1|711|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-52|1|713|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-53|1|713|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-54|1|721|Other deterministic changes|Other local manifestations and miscellaneus|Xanthogranulomatosis|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-55|1|728|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-56|1|734|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-57|1|734|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-58|1|737|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-59|1|737|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-60|1|738|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 218 - neoplasm|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-61|1|742|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-62|1|742|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 218 - neoplasm|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-63|1|743|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-64|1|744|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-65|1|745|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-66|1|754|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-67|1|762|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-68|1|763|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-69|1|765|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-70|1|768|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-71|1|769|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-72|1|775|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-73|1|776|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-74|1|776|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-75|1|776|Neoplasia systemic|Haematolymphatic system|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-76|1|784|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-77|1|790|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-78|1|793|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-79|1|800|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-80|1|800|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-81|1|803|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-82|1|804|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-83|1|806|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-84|1|810|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-85|1|810|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-86|1|828|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-87|1|831|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-88|1|831|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-89|1|833|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-90|1|841|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-91|1|841|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-92|1|843|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|head,MPATH: 446 - squamous cell carcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-93|1|843|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-94|1|854|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-95|1|855|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-96|1|856|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-97|1|859|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-98|1|864|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-99|1|867|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-100|1|869|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-101|1|872|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-102|1|873|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-103|1|874|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 218 - neoplasm|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-104|1|877|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-105|1|878|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-106|1|882|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 549 - carcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-107|1|888|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-108|1|889|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-109|1|901|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-110|1|907|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-111|1|908|Neoplasia benign|Pancreas among hepato-pancreatic system diseases|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-112|1|911|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-113|1|918|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-114|1|919|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-115|1|920|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-116|1|920|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-117|1|924|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-118|1|925|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-119|1|927|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-120|1|930|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-121|1|930|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-122|1|936|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-123|1|936|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-124|1|948|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-125|1|948|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-126|1|950|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-127|1|964|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-128|1|967|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-129|1|969|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-130|1|978|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 218 - neoplasm|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-131|1|979|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-132|1|987|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-133|1|992|Neoplasia systemic|Haematolymphatic system|spleen|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-134|1|1007|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-135|1|1009|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-136|1|1010|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 218 - neoplasm|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-137|1|1012|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-138|1|1017|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-139|1|1017|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-140|1|1017|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-141|1|1023|Neoplasia unclassified|Ovary among reproductive system diseases|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-142|1|1024|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-143|1|1032|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-144|1|1034|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-145|1|1044|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-146|1|1045|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 218 - neoplasm|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-147|1|1049|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-148|1|1049|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-149|1|1050|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-150|1|1052|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-151|1|1056|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-152|1|1057|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-153|1|1083|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 218 - neoplasm|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-154|1|1084|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-155|1|1084|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-156|1|1087|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-157|1|1087|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-158|1|1087|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-159|1|1100|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-160|1|1117|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-161|1|1125|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-162|1|1133|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-163|1|1138|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-164|1|1140|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-165|1|1153|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-166|1|1170|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 218 - neoplasm|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-167|1|1173|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-168|1|1179|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-169|1|1181|Neoplasia unclassified|Ovary among reproductive system diseases|cell|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-170|1|1189|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-171|1|1189|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-172|1|1189|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-173|1|1189|Other deterministic changes|Whole body|n/a|
4-4-1|Zr0-Th 0,n/a|1|84|shamexposed|0|unit code not relevant|not applicable or not supplied|Control|174 (174 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-1-174|1|1189|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-1|2|279|Other deterministic changes|Whole body|n/a|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-2|2|288|Other deterministic changes|Whole body|n/a|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-3|2|384|Other deterministic changes|Whole body|n/a|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-4|2|452|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 549 - carcinoma|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-5|2|496|Neoplasia benign|Integumentary system,MA: 0000151 - skin|,MPATH: 407 - fibroma|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-6|2|506|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-7|2|517|Other deterministic changes|Whole body|n/a|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-8|2|526|Other deterministic changes|Whole body|n/a|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-9|2|560|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-10|2|587|Other deterministic changes|Whole body|n/a|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-11|2|611|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-12|2|619|Neoplasia benign|Other local manifestations and miscellaneus|n/a|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-13|2|622|Other deterministic changes|Whole body|n/a|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-14|2|628|Other deterministic changes|Whole body|n/a|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-15|2|647|Other deterministic changes|Whole body|n/a|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-16|2|662|Other deterministic changes|Whole body|n/a|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-17|2|668|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-18|2|669|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-19|2|685|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-20|2|716|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-21|2|716|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-22|2|730|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-23|2|733|Other deterministic changes|Whole body|n/a|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-24|2|761|Other deterministic changes|Whole body|n/a|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-25|2|766|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-26|2|817|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-27|2|818|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-28|2|831|Other deterministic changes|Whole body|n/a|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-29|2|832|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|intestine unknown type,MPATH: 549 - carcinoma|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-30|2|839|Other deterministic changes|Whole body|n/a|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-31|2|839|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-32|2|848|Other deterministic changes|Whole body|n/a|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-33|2|853|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-34|2|857|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-35|2|857|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-36|2|879|Other deterministic changes|Whole body|n/a|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-37|2|881|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-38|2|882|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-39|2|888|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-40|2|898|Other deterministic changes|Whole body|n/a|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-41|2|912|Other deterministic changes|Whole body|n/a|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-42|2|921|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-43|2|931|Other deterministic changes|Whole body|n/a|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-44|2|940|Neoplasia systemic|Haematolymphatic system|n/a|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-45|2|941|Other deterministic changes|Whole body|n/a|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-46|2|950|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-47|2|959|Other deterministic changes|Whole body|n/a|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-48|2|977|Other deterministic changes|Whole body|n/a|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-49|2|1002|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-50|2|1008|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-51|2|1026|Other deterministic changes|Whole body|n/a|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-52|2|1028|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-53|2|1038|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-54|2|1047|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-55|2|1121|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-56|2|1140|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-2|Zr12+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|120|microliters|Injection, intravenous|120l 13% w/v|57 (57 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-2-57|2|1189|Other deterministic changes|Whole body|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-1|3|265|Other deterministic changes|Whole body|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-2|3|416|Other deterministic changes|Whole body|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-3|3|545|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-4|3|592|Other deterministic changes|Whole body|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-5|3|593|Other deterministic changes|Whole body|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-6|3|607|Other deterministic changes|Whole body|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-7|3|617|Other deterministic changes|Whole body|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-8|3|649|Other deterministic changes|Whole body|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-9|3|649|Other deterministic changes|Whole body|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-10|3|675|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-11|3|686|Other deterministic changes|Whole body|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-12|3|692|Other deterministic changes|Whole body|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-13|3|699|Other deterministic changes|Whole body|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-14|3|706|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-15|3|718|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-16|3|730|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-17|3|737|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-18|3|752|Other deterministic changes|Whole body|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-19|3|756|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-20|3|758|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-21|3|781|Other deterministic changes|Whole body|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-22|3|790|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-23|3|793|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-24|3|797|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-25|3|805|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-26|3|810|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|art,MPATH: 218 - neoplasm|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-27|3|817|Other deterministic changes|Whole body|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-28|3|820|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-29|3|821|Other deterministic changes|Whole body|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-30|3|824|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-31|3|824|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-32|3|830|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 218 - neoplasm|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-33|3|841|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-34|3|859|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-35|3|868|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-36|3|891|Neoplasia benign|Other local manifestations and miscellaneus|kidney|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-37|3|891|Other deterministic changes|Whole body|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-38|3|904|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-39|3|923|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-40|3|923|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-41|3|938|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-42|3|953|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-43|3|965|Other deterministic changes|Whole body|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-44|3|967|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-45|3|973|Other deterministic changes|Whole body|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-46|3|974|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-47|3|986|Other deterministic changes|Whole body|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-48|3|1018|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 218 - neoplasm|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-49|3|1022|Other deterministic changes|Whole body|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-50|3|1046|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-51|3|1061|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-52|3|1068|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-53|3|1075|Other deterministic changes|Whole body|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-54|3|1110|Other deterministic changes|Whole body|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-55|3|1121|Other deterministic changes|Whole body|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-56|3|1178|Neoplasia unclassified|Ovary among reproductive system diseases|n/a|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-57|3|1189|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-3|Zr300+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|300|microliters|Injection, intravenous|300l 13%|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-3-58|3|1189|Other deterministic changes|Whole body|n/a|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-1|4|191|Other deterministic changes|Whole body|n/a|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-2|4|472|Other deterministic changes|Whole body|n/a|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-3|4|539|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-4|4|553|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-5|4|553|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-6|4|566|Neoplasia systemic|Haematolymphatic system|n/a|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-7|4|595|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-8|4|622|Other deterministic changes|Whole body|n/a|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-9|4|626|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-10|4|633|Other deterministic changes|Whole body|n/a|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-11|4|643|Other deterministic changes|Whole body|n/a|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-12|4|657|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-13|4|663|Other deterministic changes|Whole body|n/a|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-14|4|672|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-15|4|686|Other deterministic changes|Whole body|n/a|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-16|4|737|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-17|4|737|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-18|4|738|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-19|4|747|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-20|4|748|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-21|4|748|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-22|4|750|Other deterministic changes|Whole body|n/a|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-23|4|756|Other deterministic changes|Whole body|n/a|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-24|4|760|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 425 - leiomyoma|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-25|4|774|Other deterministic changes|Whole body|n/a|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-26|4|783|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-27|4|790|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-28|4|790|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-29|4|790|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-30|4|815|Other deterministic changes|Whole body|n/a|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-31|4|855|Neoplasia benign|Other local manifestations and miscellaneus|n/a|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-32|4|856|Other deterministic changes|Whole body|n/a|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-33|4|864|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-34|4|870|Other deterministic changes|Whole body|n/a|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-35|4|877|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-36|4|877|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-37|4|878|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-38|4|879|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-39|4|896|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-40|4|909|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-41|4|916|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-42|4|920|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-43|4|923|Other deterministic changes|Whole body|n/a|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-44|4|924|Other deterministic changes|Whole body|n/a|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-45|4|954|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-46|4|966|Other deterministic changes|Whole body|n/a|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-47|4|998|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-48|4|1000|Other deterministic changes|Whole body|n/a|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-49|4|1010|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-50|4|1020|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-51|4|1039|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-52|4|1040|Neoplasia unclassified|Ovary among reproductive system diseases|n/a|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-53|4|1046|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-54|4|1064|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-55|4|1084|Neoplasia benign|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 270 - adenoma|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-56|4|1108|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-57|4|1120|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-58|4|1123|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-4|Zr600+Th 0,n/a|1|84|ZrO2 (Zirconotrast colloid)|600|relative dose rate|Injection, intravenous|600l 13%|59 (59 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-4-59|4|1189|Neoplasia unclassified|Ovary among reproductive system diseases|n/a|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-1|5|342|Other deterministic changes|Whole body|n/a|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-2|5|426|Other deterministic changes|Whole body|n/a|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-3|5|454|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-4|5|536|Other deterministic changes|Whole body|n/a|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-5|5|555|Other deterministic changes|Whole body|n/a|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-6|5|615|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-7|5|624|Other deterministic changes|Whole body|n/a|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-8|5|634|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-9|5|643|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-10|5|653|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-11|5|667|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 425 - leiomyoma|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-12|5|671|Other deterministic changes|Whole body|n/a|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-13|5|674|Other deterministic changes|Whole body|n/a|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-14|5|685|Other deterministic changes|Whole body|n/a|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-15|5|706|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-16|5|718|Other deterministic changes|Whole body|n/a|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-17|5|720|Other deterministic changes|Whole body|n/a|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-18|5|723|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-19|5|743|Other deterministic changes|Whole body|n/a|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-20|5|747|Neoplasia systemic|Haematolymphatic system|n/a|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-21|5|760|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-22|5|763|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-23|5|769|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-24|5|779|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-25|5|779|Other deterministic changes|Whole body|n/a|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-26|5|785|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-27|5|785|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-28|5|813|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-29|5|815|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-30|5|821|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-31|5|833|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 218 - neoplasm|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-32|5|839|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-33|5|853|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-34|5|857|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-35|5|867|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-36|5|890|Other deterministic changes|Whole body|n/a|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-37|5|892|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-38|5|892|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-39|5|905|Other deterministic changes|Whole body|n/a|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-40|5|921|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-41|5|938|Other deterministic changes|Whole body|n/a|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-42|5|963|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-43|5|969|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 218 - neoplasm|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-44|5|988|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-45|5|1008|Neoplasia benign|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 270 - adenoma|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-46|5|1009|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-47|5|1011|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-48|5|1019|Other deterministic changes|Whole body|n/a|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-49|5|1026|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-50|5|1030|Other deterministic changes|Whole body|n/a|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-51|5|1039|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-52|5|1045|Other deterministic changes|Whole body|n/a|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-53|5|1051|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 218 - neoplasm|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-54|5|1055|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-55|5|1068|Other deterministic changes|Whole body|n/a|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-56|5|1071|Other deterministic changes|Whole body|n/a|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-57|5|1095|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-58|5|1131|Neoplasia malignant|Adrenal gland  among endocrine systems|n/a|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-59|5|1176|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|tail,MPATH: 446 - squamous cell carcinoma|
4-4-5|Zr120+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|120l Th230 914Bq/ml + Th228499 Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-5-60|5|1188|Neoplasia benign|Other local manifestations and miscellaneus|n/a|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-1|6|7|Other deterministic changes|Whole body|n/a|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-2|6|370|Other deterministic changes|Whole body|n/a|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-3|6|434|Other deterministic changes|Whole body|n/a|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-4|6|449|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-5|6|464|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-6|6|524|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-7|6|526|Other deterministic changes|Whole body|n/a|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-8|6|545|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-9|6|564|Other deterministic changes|Whole body|n/a|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-10|6|573|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-11|6|619|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-12|6|621|Other deterministic changes|Whole body|n/a|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-13|6|632|Hyperplastic changes|Hepato-pancreatic system,MA: 0000358 - liver|,MPATH: 484 - hyperplastic nodule|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-14|6|644|Other deterministic changes|Whole body|n/a|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-15|6|676|Other deterministic changes|Whole body|n/a|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-16|6|680|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-17|6|685|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-18|6|689|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-19|6|692|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-20|6|693|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-21|6|696|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-22|6|713|Other deterministic changes|Whole body|n/a|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-23|6|722|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-24|6|756|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-25|6|772|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-26|6|777|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-27|6|778|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-28|6|781|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-29|6|793|Neoplasia malignant|Adrenal gland  among endocrine systems|n/a|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-30|6|798|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-31|6|820|Neoplasia benign|Integumentary system,MA: 0000151 - skin|,MPATH: 218 - neoplasm|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-32|6|824|Other deterministic changes|Whole body|n/a|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-33|6|828|Neoplasia malignant|Other local manifestations and miscellaneus|anal|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-34|6|845|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-35|6|846|Other deterministic changes|Whole body|n/a|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-36|6|847|Hyperplastic changes|Hepato-pancreatic system,MA: 0000358 - liver|,MPATH: 484 - hyperplastic nodule|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-37|6|847|Hyperplastic changes|Hepato-pancreatic system,MA: 0000358 - liver|,MPATH: 484 - hyperplastic nodule|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-38|6|865|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-39|6|870|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-40|6|878|Neoplasia malignant|Other local manifestations and miscellaneus|anal|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-41|6|890|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-42|6|891|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-43|6|893|Other deterministic changes|Whole body|n/a|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-44|6|896|Other deterministic changes|Whole body|n/a|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-45|6|924|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|lymphnode,MPATH: 513 - Lymphoid neoplasms|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-46|6|930|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-47|6|932|Other deterministic changes|Whole body|n/a|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-48|6|936|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-49|6|956|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 218 - neoplasm|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-50|6|956|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-51|6|957|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-52|6|1002|Other deterministic changes|Whole body|n/a|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-53|6|1002|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-54|6|1049|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-55|6|1063|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|fibrosarcoma,MPATH: 551 - sarcoma|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-56|6|1073|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 218 - neoplasm|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-57|6|1100|Neoplasia malignant|Adrenal gland  among endocrine systems|n/a|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-58|6|1123|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-59|6|1163|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-6|Zr300+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|300l Th230 914Bq/ml + Th228 499Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-6-60|6|1189|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-1|7|3|Other deterministic changes|Whole body|n/a|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-2|7|523|Other deterministic changes|Whole body|n/a|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-3|7|533|Other deterministic changes|Whole body|n/a|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-4|7|566|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-5|7|580|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-6|7|593|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-7|7|615|Other deterministic changes|Whole body|n/a|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-8|7|615|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-9|7|631|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-10|7|649|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 218 - neoplasm|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-11|7|652|Other deterministic changes|Whole body|n/a|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-12|7|673|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-13|7|678|Neoplasia unclassified|Other local manifestations and miscellaneus,MA: 0000003 - organ system|uterus,MPATH: 218 - neoplasm|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-14|7|684|Other deterministic changes|Whole body|n/a|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-15|7|685|Other deterministic changes|Whole body|n/a|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-16|7|700|Neoplasia unclassified|Nervous system and special sense organs|n/a|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-17|7|703|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-18|7|713|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-19|7|718|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-20|7|747|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-21|7|755|Other deterministic changes|Whole body|n/a|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-22|7|758|Other deterministic changes|Whole body|n/a|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-23|7|765|Other deterministic changes|Whole body|n/a|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-24|7|776|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-25|7|776|Neoplasia systemic|Haematolymphatic system|n/a|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-26|7|785|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-27|7|790|Other deterministic changes|Whole body|n/a|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-28|7|797|Other deterministic changes|Whole body|n/a|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-29|7|798|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-30|7|802|Other deterministic changes|Whole body|n/a|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-31|7|804|Other deterministic changes|Whole body|n/a|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-32|7|813|Other deterministic changes|Whole body|n/a|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-33|7|818|Other deterministic changes|Whole body|n/a|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-34|7|829|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-35|7|836|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-36|7|841|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-37|7|842|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-38|7|842|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-39|7|846|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-40|7|860|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-41|7|891|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-42|7|895|Other deterministic changes|Whole body|n/a|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-43|7|910|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-44|7|912|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-45|7|912|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 218 - neoplasm|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-46|7|927|Other deterministic changes|Whole body|n/a|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-47|7|928|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-48|7|950|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 218 - neoplasm|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-49|7|966|Other deterministic changes|Whole body|n/a|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-50|7|968|Neoplasia malignant|Other local manifestations and miscellaneus|mediastinum|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-51|7|1003|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-52|7|1003|Neoplasia malignant|Bone among musculo-skeletal system diseases|hindlegs|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-53|7|1052|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|bone,MPATH: 513 - Lymphoid neoplasms|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-54|7|1060|Neoplasia unclassified|Ovary among reproductive system diseases|thecoma|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-55|7|1066|Other deterministic changes|Whole body|n/a|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-56|7|1070|Other deterministic changes|Whole body|n/a|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-57|7|1178|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-7|Zr600+Th 1,n/a|1|84|Th-230 + Th-228|2|relative dose rate|Injection, intravenous|600l Th230 914Bq/ml + Th228 499Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-7-58|7|1180|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-1|8|485|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-2|8|503|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-3|8|530|Other deterministic changes|Whole body|n/a|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-4|8|538|Other deterministic changes|Whole body|n/a|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-5|8|548|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-6|8|549|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-7|8|571|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-8|8|587|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-9|8|607|Other deterministic changes|Whole body|n/a|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-10|8|626|Other deterministic changes|Whole body|n/a|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-11|8|633|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-12|8|653|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-13|8|670|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-14|8|675|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-15|8|675|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-16|8|679|Other deterministic changes|Whole body|n/a|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-17|8|696|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-18|8|702|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 549 - carcinoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-19|8|720|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-20|8|730|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-21|8|735|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-22|8|758|Other deterministic changes|Whole body|n/a|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-23|8|760|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-24|8|778|Other deterministic changes|Whole body|n/a|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-25|8|778|Other deterministic changes|Whole body|n/a|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-26|8|793|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-27|8|798|Other deterministic changes|Whole body|n/a|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-28|8|803|Other deterministic changes|Whole body|n/a|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-29|8|804|Other deterministic changes|Whole body|n/a|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-30|8|812|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-31|8|821|Other deterministic changes|Whole body|n/a|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-32|8|824|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-33|8|833|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-34|8|843|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-35|8|855|Hyperplastic changes|Hepato-pancreatic system,MA: 0000358 - liver|,MPATH: 484 - hyperplastic nodule|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-36|8|860|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-37|8|864|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-38|8|870|Other deterministic changes|Whole body|n/a|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-39|8|874|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|neck,MPATH: 446 - squamous cell carcinoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-40|8|876|Other deterministic changes|Whole body|n/a|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-41|8|876|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-42|8|879|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-43|8|883|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-44|8|891|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-45|8|911|Other deterministic changes|Whole body|n/a|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-46|8|922|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-47|8|937|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-48|8|943|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-49|8|951|Other deterministic changes|Whole body|n/a|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-50|8|964|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-51|8|967|Other deterministic changes|Whole body|n/a|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-52|8|971|Other deterministic changes|Whole body|n/a|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-53|8|988|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-54|8|1011|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-55|8|1016|Neoplasia systemic|Haematolymphatic system|spleen|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-56|8|1019|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-57|8|1020|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-58|8|1083|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-59|8|1151|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-4-8|Zr120+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|120l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-8-60|8|1153|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-1|9|486|Other deterministic changes|Whole body|n/a|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-2|9|503|Other deterministic changes|Whole body|n/a|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-3|9|529|Other deterministic changes|Whole body|n/a|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-4|9|588|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-5|9|594|Other deterministic changes|Whole body|n/a|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-6|9|601|Other deterministic changes|Whole body|n/a|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-7|9|620|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-8|9|637|Other deterministic changes|Whole body|head|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-9|9|637|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-10|9|663|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-11|9|674|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-12|9|678|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-13|9|680|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-14|9|703|Other deterministic changes|Whole body|n/a|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-15|9|707|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-16|9|714|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-17|9|723|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-18|9|723|Other deterministic changes|Whole body|n/a|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-19|9|728|Neoplasia unclassified|Central nervous system among nervous system|n/a|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-20|9|743|Other deterministic changes|Whole body|n/a|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-21|9|747|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-22|9|755|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-23|9|756|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-24|9|763|Other deterministic changes|Whole body|n/a|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-25|9|778|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-26|9|782|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-27|9|784|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-28|9|788|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-29|9|793|Neoplasia malignant|Other local manifestations and miscellaneus|hindlegs|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-30|9|802|Other deterministic changes|Whole body|n/a|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-31|9|832|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-32|9|853|Other deterministic changes|Whole body|n/a|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-33|9|860|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-34|9|867|Neoplasia benign|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 277 - cystadenoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-35|9|872|Other deterministic changes|Whole body|n/a|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-36|9|890|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|carcinoma,MPATH: 218 - neoplasm|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-37|9|891|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 549 - carcinoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-38|9|895|Other deterministic changes|Whole body|n/a|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-39|9|902|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-40|9|923|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-41|9|923|Other deterministic changes|Whole body|n/a|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-42|9|936|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|forelegs,MPATH: 446 - squamous cell carcinoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-43|9|937|Other deterministic changes|Whole body|n/a|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-44|9|938|Other deterministic changes|Whole body|n/a|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-45|9|939|Other deterministic changes|Whole body|n/a|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-46|9|945|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-47|9|946|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 74 - hamartoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-48|9|948|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-49|9|954|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-50|9|988|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-51|9|997|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-52|9|1003|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-53|9|1020|Neoplasia benign|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 270 - adenoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-54|9|1024|Other deterministic changes|Whole body|n/a|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-55|9|1030|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-56|9|1032|Other deterministic changes|Whole body|n/a|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-57|9|1084|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 74 - hamartoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-58|9|1084|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-59|9|1123|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-9|Zr300+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|300l  Th230 2287Bq/ml+ Th228 2351Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-9-60|9|1126|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-1|10|367|Other deterministic changes|Whole body|n/a|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-2|10|472|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-3|10|490|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-4|10|519|Other deterministic changes|Whole body|n/a|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-5|10|521|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-6|10|580|Other deterministic changes|Whole body|n/a|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-7|10|615|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|neck,MPATH: 446 - squamous cell carcinoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-8|10|616|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-9|10|626|Other deterministic changes|Whole body|n/a|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-10|10|643|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-11|10|656|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-12|10|659|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-13|10|663|Other deterministic changes|Whole body|n/a|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-14|10|692|Other deterministic changes|Whole body|n/a|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-15|10|706|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-16|10|716|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-17|10|727|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-18|10|737|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|lung,MPATH: 513 - Lymphoid neoplasms|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-19|10|759|Other deterministic changes|Whole body|n/a|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-20|10|761|Hyperplastic changes|Hepato-pancreatic system,MA: 0000358 - liver|,MPATH: 484 - hyperplastic nodule|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-21|10|783|Other deterministic changes|Whole body|n/a|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-22|10|793|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-23|10|793|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-24|10|801|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-25|10|805|Other deterministic changes|Whole body|n/a|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-26|10|822|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-27|10|841|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-28|10|845|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-29|10|848|Other deterministic changes|Whole body|n/a|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-30|10|854|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-31|10|856|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-32|10|857|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|horned,MPATH: 268 - adenocarcinoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-33|10|883|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-34|10|900|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-35|10|903|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-36|10|912|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-37|10|918|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-38|10|927|Other deterministic changes|Whole body|n/a|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-39|10|930|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-40|10|930|Other deterministic changes|Whole body|n/a|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-41|10|947|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-42|10|948|Other deterministic changes|Whole body|n/a|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-43|10|959|Other deterministic changes|Whole body|n/a|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-44|10|973|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-45|10|999|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 549 - carcinoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-46|10|1002|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-47|10|1014|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-48|10|1044|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-49|10|1064|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-50|10|1072|Neoplasia malignant|Other local manifestations and miscellaneus|tail|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-51|10|1077|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-52|10|1077|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-53|10|1078|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-54|10|1083|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|mamma,MPATH: 513 - Lymphoid neoplasms|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-55|10|1108|Other deterministic changes|Whole body|n/a|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-56|10|1114|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 218 - neoplasm|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-57|10|1146|Neoplasia benign|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 270 - adenoma|
4-4-10|Zr600+Th 2.5,n/a|1|84|Th-230 + Th-228|5|relative dose rate|Injection, intravenous|600l  Th230 2287Bq/ml+ Th228 2351Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-10-58|10|1169|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-1|11|452|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-2|11|462|Other deterministic changes|Whole body|n/a|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-3|11|513|Other deterministic changes|Whole body|n/a|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-4|11|513|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-5|11|513|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-6|11|517|Other deterministic changes|Whole body|n/a|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-7|11|546|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-8|11|558|Other deterministic changes|Whole body|n/a|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-9|11|579|Neoplasia systemic|Haematolymphatic system|n/a|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-10|11|586|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-11|11|606|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-12|11|618|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-13|11|620|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-14|11|631|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 551 - sarcoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-15|11|668|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-16|11|677|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-17|11|685|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-18|11|687|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-19|11|718|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-20|11|734|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-21|11|746|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-22|11|753|Neoplasia systemic|Haematolymphatic system|spleen|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-23|11|767|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-24|11|768|Neoplasia unclassified|Nervous system and special sense organs|mamma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-25|11|782|Other deterministic changes|Whole body|n/a|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-26|11|789|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-27|11|789|Neoplasia systemic|Haematolymphatic system|n/a|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-28|11|801|Other deterministic changes|Whole body|n/a|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-29|11|805|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-30|11|824|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-31|11|844|Other deterministic changes|Whole body|n/a|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-32|11|849|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-33|11|851|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-34|11|866|Neoplasia systemic|Haematolymphatic system|kidney|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-35|11|883|Other deterministic changes|Whole body|n/a|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-36|11|886|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-37|11|887|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-38|11|887|Other deterministic changes|Whole body|n/a|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-39|11|897|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-40|11|929|Other deterministic changes|Whole body|n/a|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-41|11|930|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 218 - neoplasm|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-42|11|934|Neoplasia malignant|Other local manifestations and miscellaneus|anal|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-43|11|939|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-44|11|941|Neoplasia malignant|Bone among musculo-skeletal system diseases|hindlegs|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-45|11|951|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-46|11|957|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-47|11|962|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-48|11|972|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-49|11|982|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 74 - hamartoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-50|11|987|Neoplasia benign|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 270 - adenoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-51|11|990|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-52|11|1001|Other deterministic changes|Whole body|n/a|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-53|11|1012|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-54|11|1024|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-55|11|1043|Neoplasia malignant|Adrenal gland  among endocrine systems|n/a|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-56|11|1049|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-57|11|1049|Neoplasia malignant|Other local manifestations and miscellaneus|neck|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-58|11|1051|Neoplasia systemic|Haematolymphatic system|lung|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-59|11|1055|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-11|Zr120+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|120l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-11-60|11|1188|Neoplasia benign|Liver among hepato-pancreatic system diseases|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-1|12|368|Other deterministic changes|Whole body|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-2|12|515|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-3|12|520|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-4|12|534|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-5|12|560|Other deterministic changes|Whole body|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-6|12|568|Other deterministic changes|Whole body|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-7|12|608|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-8|12|614|Other deterministic changes|Whole body|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-9|12|631|Hyperplastic changes|Hepato-pancreatic system,MA: 0000358 - liver|,MPATH: 484 - hyperplastic nodule|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-10|12|635|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-11|12|635|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-12|12|636|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-13|12|637|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-14|12|642|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-15|12|659|Other deterministic changes|Whole body|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-16|12|670|Other deterministic changes|Whole body|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-17|12|679|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-18|12|684|Neoplasia systemic|Haematolymphatic system|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-19|12|684|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-20|12|686|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-21|12|698|Other deterministic changes|Whole body|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-22|12|700|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-23|12|701|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-24|12|712|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-25|12|722|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-26|12|723|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-27|12|726|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-28|12|734|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-29|12|736|Neoplasia unclassified|Central nervous system among nervous system|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-30|12|740|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-31|12|740|Other deterministic changes|Whole body|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-32|12|743|Other deterministic changes|Whole body|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-33|12|749|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-34|12|751|Other deterministic changes|Whole body|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-35|12|765|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-36|12|768|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-37|12|770|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-38|12|770|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-39|12|782|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-40|12|791|Other deterministic changes|Whole body|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-41|12|797|Neoplasia systemic|Haematolymphatic system|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-42|12|799|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000003 - organ system|,MPATH: 551 - sarcoma|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-43|12|805|Other deterministic changes|Whole body|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-44|12|824|Other deterministic changes|Whole body|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-45|12|830|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 218 - neoplasm|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-46|12|838|Other deterministic changes|Whole body|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-47|12|848|Other deterministic changes|Whole body|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-48|12|852|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|neck,MPATH: 446 - squamous cell carcinoma|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-49|12|857|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-50|12|880|Other deterministic changes|Whole body|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-51|12|894|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 218 - neoplasm|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-52|12|927|Neoplasia unclassified|Nervous system and special sense organs|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-53|12|934|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-54|12|967|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-55|12|998|Other deterministic changes|Whole body|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-56|12|1010|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|anal,MPATH: 446 - squamous cell carcinoma|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-57|12|1015|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-58|12|1049|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|lymphnode,MPATH: 513 - Lymphoid neoplasms|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-59|12|1066|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-12|Zr300+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|300l  Th230 4570Bq/ml+ Th228 2498Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-12-60|12|1183|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-1|13|376|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-2|13|544|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-3|13|547|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-4|13|565|Other deterministic changes|Whole body|n/a|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-5|13|567|Neoplasia benign|Bloodvessels among cardiovascular system|n/a|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-6|13|583|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-7|13|593|Other deterministic changes|Whole body|n/a|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-8|13|635|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-9|13|649|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-10|13|663|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-11|13|677|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-12|13|698|Other deterministic changes|Whole body|n/a|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-13|13|702|Other deterministic changes|Whole body|n/a|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-14|13|719|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-15|13|722|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-16|13|726|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-17|13|742|Other deterministic changes|Whole body|n/a|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-18|13|747|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-19|13|747|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-20|13|754|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000003 - organ system|,MPATH: 551 - sarcoma|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-21|13|762|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-22|13|783|Other deterministic changes|Whole body|n/a|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-23|13|801|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-24|13|822|Other deterministic changes|Whole body|n/a|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-25|13|827|Other deterministic changes|Whole body|n/a|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-26|13|827|Other deterministic changes|Whole body|n/a|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-27|13|838|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-28|13|844|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-29|13|863|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-30|13|863|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-31|13|866|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-32|13|869|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-33|13|871|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-34|13|879|Other deterministic changes|Whole body|n/a|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-35|13|887|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-36|13|891|Other deterministic changes|Whole body|n/a|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-37|13|891|Neoplasia benign|Lower respiratory system|n/a|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-38|13|895|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-39|13|901|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-40|13|910|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-41|13|915|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-42|13|935|Other deterministic changes|Whole body|n/a|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-43|13|942|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-44|13|942|Neoplasia benign|Lower respiratory system|n/a|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-45|13|945|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|neck,MPATH: 513 - Lymphoid neoplasms|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-46|13|955|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-47|13|957|Other deterministic changes|Whole body|n/a|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-48|13|973|Neoplasia benign|Other local manifestations and miscellaneus|n/a|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-49|13|988|Other deterministic changes|Whole body|n/a|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-50|13|991|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-51|13|1050|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-52|13|1058|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-53|13|1060|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-54|13|1068|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|lung,MPATH: 513 - Lymphoid neoplasms|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-55|13|1120|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-56|13|1139|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-57|13|1147|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 218 - neoplasm|
4-4-13|Zr600+Th 5,n/a|1|84|Th-230 + Th-228|10|relative dose rate|Injection, intravenous|600l  Th230 4570Bq/ml+ Th228 2498Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-13-58|13|1160|Other deterministic changes|Whole body|n/a|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-1|14|383|Other deterministic changes|Whole body|n/a|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-2|14|507|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-3|14|536|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-4|14|544|Other deterministic changes|Whole body|n/a|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-5|14|553|Other deterministic changes|Whole body|n/a|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-6|14|557|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-7|14|560|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-8|14|562|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-9|14|567|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-10|14|568|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-11|14|582|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-12|14|595|Other deterministic changes|Whole body|n/a|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-13|14|616|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-14|14|618|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-15|14|631|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 240 - hemangioma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-16|14|646|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-17|14|650|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-18|14|663|Other deterministic changes|Whole body|n/a|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-19|14|677|Hyperplastic changes|Hepato-pancreatic system,MA: 0000358 - liver|,MPATH: 484 - hyperplastic nodule|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-20|14|677|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-21|14|686|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-22|14|690|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 218 - neoplasm|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-23|14|694|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-24|14|717|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-25|14|723|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-26|14|736|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-27|14|741|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-28|14|744|Neoplasia systemic|Haematolymphatic system|spleen|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-29|14|746|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-30|14|746|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-31|14|758|Other deterministic changes|Whole body|n/a|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-32|14|762|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-33|14|765|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-34|14|782|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-35|14|784|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-36|14|785|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-37|14|786|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-38|14|795|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-39|14|797|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-40|14|799|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-41|14|809|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-42|14|818|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-43|14|825|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-44|14|827|Neoplasia systemic|Haematolymphatic system|uterus|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-45|14|829|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-46|14|838|Neoplasia unclassified|Central nervous system among nervous system|n/a|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-47|14|839|Other deterministic changes|Whole body|n/a|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-48|14|855|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 74 - hamartoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-49|14|858|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-50|14|865|Other deterministic changes|Whole body|n/a|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-51|14|883|Neoplasia systemic|Haematolymphatic system|forelegs|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-52|14|896|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-53|14|897|Other deterministic changes|Whole body|n/a|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-54|14|918|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-55|14|953|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-56|14|968|Neoplasia systemic|Haematolymphatic system|n/a|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-57|14|970|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-58|14|983|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-59|14|1006|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-14|Zr120+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|120l  Th230 9139Bq/ml+ Th228 4995Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-14-60|14|1053|Neoplasia systemic|Haematolymphatic system|spleen|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-1|15|140|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-2|15|364|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-3|15|418|Other deterministic changes|Whole body|n/a|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-4|15|460|Other deterministic changes|Whole body|n/a|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-5|15|474|Other deterministic changes|Whole body|n/a|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-6|15|474|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-7|15|484|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-8|15|542|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-9|15|568|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|horned,MPATH: 268 - adenocarcinoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-10|15|580|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-11|15|580|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-12|15|581|Neoplasia benign|Bloodvessels among cardiovascular system|n/a|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-13|15|610|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-14|15|614|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-15|15|621|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-16|15|633|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-17|15|649|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-18|15|651|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-19|15|656|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-20|15|656|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-21|15|670|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-22|15|684|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-23|15|686|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-24|15|687|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 218 - neoplasm|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-25|15|694|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-26|15|700|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-27|15|714|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-28|15|748|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-29|15|757|Other deterministic changes|Whole body|n/a|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-30|15|762|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-31|15|774|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-32|15|775|Other deterministic changes|Whole body|n/a|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-33|15|784|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-34|15|786|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-35|15|789|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-36|15|791|Other deterministic changes|Whole body|n/a|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-37|15|802|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-38|15|806|Other deterministic changes|Whole body|n/a|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-39|15|815|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-40|15|824|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-41|15|830|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-42|15|849|Hyperplastic changes|Other local manifestations and miscellaneus|Lung hyperplastic nodule|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-43|15|865|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-44|15|871|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-45|15|877|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-46|15|888|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-47|15|888|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-48|15|891|Other deterministic changes|Whole body|n/a|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-49|15|901|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-50|15|908|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-51|15|912|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-52|15|921|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-53|15|937|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-54|15|943|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-55|15|976|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-56|15|1002|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-57|15|1012|Neoplasia benign|Other local manifestations and miscellaneus|hindlegs|
4-4-15|Zr300+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|300l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-15-58|15|1014|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-1|16|278|Neoplasia systemic|Haematolymphatic system|n/a|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-2|16|448|Other deterministic changes|Whole body|n/a|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-3|16|450|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-4|16|462|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-5|16|466|Neoplasia benign|Liver among hepato-pancreatic system diseases|n/a|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-6|16|469|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-7|16|530|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-8|16|532|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-9|16|538|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-10|16|572|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-11|16|601|Neoplasia benign|Bloodvessels among cardiovascular system|Bauchhoehle|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-12|16|603|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000003 - organ system|hindlegs,MPATH: 551 - sarcoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-13|16|604|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-14|16|610|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-15|16|614|Neoplasia benign|Integumentary system,MA: 0000151 - skin|anal,MPATH: 218 - neoplasm|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-16|16|619|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-17|16|624|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-18|16|642|Other deterministic changes|Whole body|n/a|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-19|16|649|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 218 - neoplasm|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-20|16|663|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-21|16|667|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-22|16|673|Other deterministic changes|Whole body|n/a|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-23|16|679|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-24|16|684|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-25|16|684|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-26|16|694|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-27|16|698|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-28|16|704|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-29|16|707|Other deterministic changes|Whole body|n/a|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-30|16|709|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-31|16|714|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-32|16|719|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-33|16|729|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-34|16|743|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-35|16|756|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-36|16|777|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-37|16|792|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-38|16|800|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-39|16|805|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-40|16|815|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-41|16|817|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-42|16|820|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-43|16|823|Hyperplastic changes|Hepato-pancreatic system,MA: 0000358 - liver|,MPATH: 484 - hyperplastic nodule|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-44|16|853|Other deterministic changes|Whole body|n/a|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-45|16|859|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-46|16|866|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-47|16|886|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-48|16|894|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-49|16|894|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-50|16|895|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-51|16|901|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-52|16|933|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-53|16|941|Other deterministic changes|Whole body|n/a|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-54|16|946|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-55|16|956|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-56|16|964|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-57|16|965|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-16|Zr600+Th 10,n/a|1|84|Th-230 + Th-228|20|relative dose rate|Injection, intravenous|600l  Th230 9139Bq/ml+ Th228 4995Bq/ml|58 (58 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-16-58|16|986|Other deterministic changes|Whole body|n/a|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-1|17|281|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-2|17|420|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-3|17|434|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-4|17|453|Other deterministic changes|Whole body|n/a|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-5|17|453|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-6|17|460|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-7|17|476|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-8|17|490|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-9|17|501|Other deterministic changes|Whole body|n/a|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-10|17|504|Hyperplastic changes|Hepato-pancreatic system,MA: 0000358 - liver|,MPATH: 484 - hyperplastic nodule|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-11|17|506|Other deterministic changes|Whole body|n/a|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-12|17|509|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-13|17|522|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-14|17|524|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-15|17|524|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-16|17|528|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-17|17|533|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-18|17|535|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-19|17|546|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-20|17|547|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-21|17|548|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-22|17|549|Other deterministic changes|Whole body|n/a|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-23|17|555|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-24|17|562|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-25|17|571|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-26|17|580|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-27|17|581|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-28|17|593|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-29|17|599|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-30|17|604|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|horned,MPATH: 268 - adenocarcinoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-31|17|610|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-32|17|611|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|hindlegs,MPATH: 513 - Lymphoid neoplasms|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-33|17|617|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-34|17|621|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-35|17|625|Other deterministic changes|Whole body|n/a|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-36|17|627|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-37|17|633|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 551 - sarcoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-38|17|642|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-39|17|646|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-40|17|653|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-41|17|656|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-42|17|658|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-43|17|659|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-44|17|661|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-45|17|674|Other deterministic changes|Whole body|n/a|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-46|17|674|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-47|17|684|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 240 - hemangioma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-48|17|693|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-49|17|704|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-50|17|705|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-51|17|709|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-52|17|709|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-53|17|711|Other deterministic changes|Whole body|n/a|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-54|17|733|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-55|17|742|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-56|17|762|Neoplasia malignant|Bone among musculo-skeletal system diseases|hindlegs|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-57|17|778|Other deterministic changes|Whole body|n/a|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-58|17|792|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-59|17|831|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-17|Zr120+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|120l  Th230 22866Bq/ml+ Th228 12509Bq/ml|60 (60 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-17-60|17|922|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-1|18|253|Other deterministic changes|Whole body|n/a|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-2|18|344|Other deterministic changes|Whole body|n/a|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-3|18|370|Other deterministic changes|Whole body|n/a|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-4|18|383|Other deterministic changes|Whole body|n/a|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-5|18|410|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 549 - carcinoma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-6|18|422|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|hindlegs,MPATH: 408 - soft tissue fibrosarcoma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-7|18|425|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-8|18|434|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-9|18|455|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-10|18|468|Other deterministic changes|Whole body|n/a|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-11|18|492|Other deterministic changes|Whole body|n/a|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-12|18|508|Other deterministic changes|Whole body|n/a|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-13|18|511|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-14|18|511|Neoplasia systemic|Haematolymphatic system|n/a|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-15|18|516|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-16|18|528|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-17|18|535|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-18|18|551|Other deterministic changes|Whole body|n/a|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-19|18|555|Other deterministic changes|Whole body|n/a|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-20|18|560|Hyperplastic changes|Hepato-pancreatic system,MA: 0000358 - liver|,MPATH: 484 - hyperplastic nodule|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-21|18|565|Other deterministic changes|Whole body|n/a|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-22|18|568|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-23|18|577|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-24|18|579|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-25|18|579|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-26|18|580|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-27|18|599|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-28|18|614|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-29|18|639|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-30|18|651|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 240 - hemangioma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-31|18|656|Other deterministic changes|Whole body|n/a|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-32|18|659|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-33|18|662|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-34|18|684|Hyperplastic changes|Hepato-pancreatic system,MA: 0000358 - liver|,MPATH: 484 - hyperplastic nodule|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-35|18|684|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-36|18|685|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-37|18|687|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-38|18|690|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-39|18|696|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-40|18|715|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-41|18|722|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-42|18|726|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-43|18|739|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-44|18|759|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-45|18|763|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-46|18|768|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-47|18|771|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-48|18|826|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-49|18|856|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-4-18|Zr300+Th 25,n/a|1|84|Th-230 + Th-228|50|relative dose rate|Injection, intravenous|300l  Th230 22866Bq/ml+ Th228 12509Bq/ml|50 (50 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan  study with microscopic/macroscopic pathology|4-4-18-50|18|933|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
